文献速递肝病消化道肿瘤与早癌

阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌患者的肝功能失代偿:一项真实世界研究

Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-02-26

这项多中心研究纳入247例接受阿替利珠单抗联合贝伐珠单抗治疗的晚期或不可切除肝细胞癌患者,评估基线肝功能及治疗期间肝功能失代偿对临床结局的预后影响。总生存期18.30个月,Child Pugh A较B患者总生存期更优(20.20 vs 9.83个月,P=0.0008),63例(25.51%)发生肝功能失代偿,失代偿后恢复治疗者总生存期与从未失代偿者相当。

要点

  • Child Pugh A与B患者总生存期分别为20.20与9.83个月,P=0.0008
  • 63例(25.51%)发生肝功能失代偿,Child Pugh A为27.89%,B为51.16%
  • 失代偿后恢复治疗者总生存期优于永久停药者(20.87 vs 8.07个月,P=0.02)

核心结论

  • 阿替利珠单抗联合贝伐珠单抗在Child Pugh A和B患者中均有效。
  • 肝功能失代偿后恢复治疗的可能性凸显了肝肿瘤综合管理的重要性。

研究设计与样本

  • 多中心研究,纳入247例接受阿替利珠单抗联合贝伐珠单抗治疗的晚期或不可切除肝细胞癌患者。
  • 分析生存、肿瘤进展和肝功能失代偿数据,并将失代偿时间作为新的安全性终点。

主要发现

  • 报告的总生存期为18.30个月,至进展时间为13.07个月,无进展生存期为9.83个月。
  • Child Pugh A较Child Pugh B患者总生存期更优(20.20 vs 9.83个月;P=0.0008),至进展时间和治疗安全性无差异。
  • 63例(25.51%)发生肝功能失代偿,其中Child Pugh A为27.89%,Child Pugh B为51.16%。
  • 41.26%的患者在失代偿后恢复阿替利珠单抗联合贝伐珠单抗治疗,总生存期与从未失代偿者相当(20.87 vs 20.2个月;P=0.77),且优于永久停药者(8.07个月;P=0.02)。
  • 白蛋白-胆红素评分2分的患者无论Child Pugh分级,失代偿时间相似;Child Pugh A和B患者从失代偿中恢复的概率相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Atezolizumab plus bevacizumab (atezobeva) has changed the treatment landscape of advanced hepatocellular carcinoma, but its efficacy and safety in patients with impaired liver function are still debated. This study aimed to evaluate the prognostic impact of baseline liver function and liver decompensation during treatment on clinical outcomes. METHODS: In this multicenter study, we included 247 patients with advanced or unresectable hepatocellular carcinoma treated with atezobeva. We analyzed data on survival, tumor progression, and liver decompensation and introduced time to decompensation as a new safety endpoint. RESULTS: The reported overall survival (OS) was 18.30 months, time to progression 13.07 months, and progression-free survival (PFS) 9.83 months. Although OS was better in Child Pugh A compared with Child Pugh B patients (20.20 vs 9.83 months; P = .0008), no differences were observed in time to progression and treatment safety. Liver decompensation occurred in 63 patients (25.51%), specifically 27.89% Child Pugh A and 51.16% Child Pugh B patients; in 41.26% of patients, atezobeva was resumed after decompensation, achieving an OS comparable to those who never decompensated (20.87 vs 20.2 months; P = .77), and better than those who permanently stopped treatment (8.07 months; P = .02). Time to decompensation was similar for patients with albumin-bilirubin score 2 regardless of Child Pugh class, and the probability of recovery from decompensation was similar for Child Pugh A and B patients. CONCLUSIONS: Atezobeva is effective in both Child Pugh A and B patients. The possibility to resume treatment after an episode of decompensation underscores the importance of integrated hepato-oncological management.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Stella L, Pallozzi M, Cerrito L, et al. Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study. Clin Gastroenterol Hepatol. 2025. PMID: 40020957. doi:10.1016/j.cgh.2024.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。